Your browser doesn't support javascript.
loading
Targeting redox-altered plasticity to reactivate synaptic function: A novel therapeutic strategy for cognitive disorder.
Wang, Pei; Wang, Fang; Ni, Lan; Wu, Pengfei; Chen, Jianguo.
Afiliação
  • Wang P; Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Wang F; Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Ni L; Key Laboratory of Neurological Diseases (HUST), Ministry of Education of China, Wuhan 430030, China.
  • Wu P; The Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Wuhan 430030, China.
  • Chen J; Laboratory of Neuropsychiatric Diseases, the Institute of Brain Research, Huazhong University of Science and Technology, Wuhan 430030, China.
Acta Pharm Sin B ; 11(3): 599-608, 2021 Mar.
Article em En | MEDLINE | ID: mdl-33777670
Redox-altered plasticity refers to redox-dependent reversible changes in synaptic plasticity via altering functions of key proteins, such as N-methyl-d-aspartate receptor (NMDAR). Age-related cognitive disorders includes Alzheimer's disease (AD), vascular dementia (VD), and age-associated memory impairment (AAMI). Based on the critical role of NMDAR-dependent long-term potentiation (LTP) in memory, the increase of reactive oxygen species in cognitive disorders, and the sensitivity of NMDAR to the redox status, converging lines have suggested the redox-altered NMDAR-dependent plasticity might underlie the synaptic dysfunctions associated with cognitive disorders. In this review, we summarize the involvement of redox-altered plasticity in cognitive disorders by presenting the available evidence. According to reports from our laboratory and other groups, this "redox-altered plasticity" is more similar to functional changes rather than organic injuries, and strategies targeting redox-altered plasticity using pharmacological agents might reverse synaptic dysfunctions and memory abnormalities in the early stage of cognitive disorders. Targeting redox modifications for NMDARs may serve as a novel therapeutic strategy for memory deficits.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acta Pharm Sin B Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acta Pharm Sin B Ano de publicação: 2021 Tipo de documento: Article